The primary objective of this study is to investigate whether Peg-IFN beta-1a improves the
satisfaction of Relapsing-Remitting Multiple Sclerosis (RRMS) participants unsatisfied with
injectable subcutaneous Interferons, as measured by the Abbreviated Treatment Satisfaction
Questionnaire to Medication (TSQM-9), at 12 weeks. The secondary objectives of this study are
to evaluate in this study population: effects of Peg-IFN beta-1a treatment on participants'
satisfaction at 24 weeks; effects of Peg-IFN beta-1a treatment on short-term participants'
adherence; effects of Peg-IFN beta-1a treatment on participants' fatigue; effects of Peg-IFN
beta-1a on disease activity and physical disability; impact of Peg-IFN beta-1a treatment on
participant-reported health-related quality of life; impact of Peg-IFN beta-1a treatment on
participants' injection-system satisfaction; Evaluate the relationship between participants'
satisfaction and adherence; Evaluate the relationship between participants' satisfaction and
social-demographic factors (age, sex, employment working, level of education, etc) and
clinical characteristics (annualized relapse rate [ARR], disability, etc.) and to evaluate
the treatment safety and tolerability.